Treating autoimmune diseases costs over $100B annually (more than cancer), but their therapies are stuck in the 20th century. We founded Karma Biotechnologies to solve this problem by developing a novel class of therapeutics we call Xavines. These are designed to specifically switch off rogue immune cells that cause autoimmunity, allergies, and food sensitivities. Karma will handle preclinical development, then partner for clinical trials.